

Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein

Jurre J. Kamphorst¹, Michel Nofal¹, Cosimo Commisso², Sean R. Hackett¹, Wenyun Lu¹, Elda Grabocka², Matthew G. Vander Heiden^{3,4}, George Miller^{5,6}, Jeffrey A. Drebin⁷, Dafna Bar-Sagi², Craig B. Thompson⁸, and Joshua D. Rabinowitz¹

Abstract

Glucose and amino acids are key nutrients supporting cell growth. Amino acids are imported as monomers, but an alternative route induced by oncogenic KRAS involves uptake of extracellular proteins via macropinocytosis and subsequent lysosomal degradation of these proteins as a source of amino acids. In this study, we examined the metabolism of pancreatic ductal adenocarcinoma (PDAC), a poorly vascularized lethal KRAS-driven malignancy. Metabolomic comparisons of human PDAC and benign adjacent tissue revealed that tumor tissue was low in glucose, upper glycolytic intermediates, creatine phosphate, and the amino acids glutamine and serine, two major metabolic substrates. Surprisingly, PDAC accumulated essential amino acids. Such accumulation could arise from

extracellular proteins being degraded through macropinocytosis in quantities necessary to meet glutamine requirements, which in turn produces excess of most other amino acids. Consistent with this hypothesis, active macropinocytosis is observed in primary human PDAC specimens. Moreover, in the presence of physiologic albumin, we found that cultured murine PDAC cells grow indefinitely in media lacking single essential amino acids and replicate once in the absence of free amino acids. Growth under these conditions was characterized by simultaneous glutamine depletion and essential amino acid accumulation. Overall, our findings argue that the scavenging of extracellular proteins is an important mode of nutrient uptake in PDAC. *Cancer Res*; 75(3): 544–53. ©2014 AACR.

Introduction

One of the most lethal forms of cancer is pancreatic ductal adenocarcinoma (PDAC; ref. 1). Almost all cases of PDAC involve activating KRAS mutations (2). In addition to driving growth, KRAS induces metabolic changes including enhanced glucose uptake, glycolytic

flux, and glucose flux into hexosamines and ribose-5-phosphate (3). In contrast to other driver oncogenes such as PI3K that broadly increase glucose flux throughout metabolism (4), oncogenic RAS impairs flux of glucose through pyruvate dehydrogenase into the tricarboxylic acid (TCA) cycle (5, 6). RAS-driven cells instead rely heavily on glutamine as a TCA carbon source, with glutamine catabolism through the TCA cycle and malic enzyme essential in pancreatic cancer cells (7). Thus, RAS-driven cancer cells are comparatively less dependent on glucose than other cancer cells (8).

Generation of significant ATP from substrates other than glucose requires oxygen, whose availability in tumors is classically limited because of poor perfusion. Indeed, PDAC tumors, which are characterized by poor vascularization and high interstitial pressure, are typically hypoxic (9, 10). Given the high metabolic demands of tumor growth, poor perfusion may lead to limitation not only for oxygen but also nutrients including glucose and free amino acids. Given the particular importance of glutamine as a source of both usable nitrogen and TCA cycle carbon, glutamine can potentially be a limiting nutrient for tumor growth. Consistent with this, studies in murine tumor models in the 1940s and 1950s found lower free glutamine in the tumor than corresponding normal tissue (11, 12).

A potential alternative to traditional uptake of monomeric amino acids via membrane transport proteins is macropinocytosis, a process activated by mutant KRAS (13, 14). Macropinocytosis involves bulk uptake of extracellular constituents, including proteins that can be subsequently digested in lysosomes into free amino acids. Intriguingly, in cell culture, feeding of albumin to RAS-driven cells enabled their survival and proliferation in low glutamine, and such survival and proliferation was dependent

¹Lewis-Sigler Institute for Integrative Genomics, Carl Icahn Laboratory, Princeton University, Princeton, New Jersey. ²Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York. ³Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts. ⁴Dana-Farber Cancer Institute, Boston, Massachusetts. ⁵Department of Surgery, New York University School of Medicine, New York, New York. ⁶Department of Cell Biology, New York University School of Medicine, New York, New York. ⁷Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. ⁸Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York.

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Current address for J.J. Kamphorst: Cancer Research UK Beatson Institute and Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1BD, United Kingdom; current address for C. Commisso: Sanford-Burnham Medical Research Institute, Cell Death and Survival Networks Program, 10901 N. Torrey Pines Road, La Jolla, CA 92037.

J.J. Kamphorst, M. Nofal, and C. Commisso contributed equally to this article.

Corresponding Author: Joshua D. Rabinowitz, Lewis-Sigler Institute for Integrative Genomics, Carl Icahn Laboratory, Princeton University, Princeton, NJ 08544. Phone: 609-258-8985; Fax: 609-258-7070; E-mail: josh@princeton.edu

doi: 10.1158/0008-5472.CAN-14-2211

©2014 American Association for Cancer Research.

upon macropinocytosis (14). Albumin has been reported to accumulate in tumors, likely due to a combination of leaky vasculature and lymphatic deficiency (15). Thus, it is conceptually possible that plasma protein leakage from tumor vasculature provides a nutrient source for cancer cells. The extent to which this actually occurs in human tumors, however, has not yet been explored. Nor has it been shown whether such scavenging is sufficient to provide amino acids other than glutamine in biologically significant quantities.

Here, we investigate protein scavenging in PDAC. Metabolomic analysis of freshly isolated human PDAC tumor specimens (compared with benign adjacent tissue) revealed that the tumors are low in glucose, upper glycolytic intermediates, glutamine, and serine. PDAC tumors also accumulated amino acids that are useful primarily for protein synthesis. Although uptake or synthesis of monomeric amino acids would be expected to yield each amino acid in quantities balanced with total demand, protein catabolism instead produces amino acids in proportion to their abundance in the catabolized protein. Those amino acids that are consumed by multiple anabolic processes (such as glutamine) would accordingly become depleted relative to those used solely or primarily for protein synthesis. Thus, the observed pattern of amino acid depletion and accumulation in human PDAC suggests a reliance on protein scavenging. Consistent with this, we find that primary human PDAC specimens display enhanced macropinocytosis. Moreover, we show that cultured pancreatic cancer cells can obtain sufficient amino acids via protein scavenging to grow with albumin as the sole amino acid source, and that this mode of growth is associated with glutamine depletion and essential amino acid accumulation.

Materials and Methods

Cell culturing and amino acid dropout experiments

KRPC cells were kindly provided by S. Lowe (Memorial Sloan-Kettering Cancer Center, New York, NY; ref. 16). These cells were harvested from a murine tumor following orthotopic injection of murine pancreas progenitor cells with endogenous KRAS^{G12D} that were additionally engineered to have MYC expression and silenced (shRNA-mediated) P53. Cell lines were routinely passaged in DMEM (Mediatech) with 25 mmol/L glucose and 4 mmol/L glutamine and supplemented with 10% (*v/v*) fetal bovine serum (FBS; HyClone), 25 IU/mL penicillin, and 25 µg/mL streptomycin (MP Biomedicals), and split at 80% confluence. For amino acid dropout experiments, pyruvate-free DMEM was prepared from powder (Cellgro, cat. no. 10-017-CV) by adding glucose (25 mmol/L), salts, vitamins, phenol red, and amino acids, except for the amino acid to be omitted. For single amino acid dropout experiments, cells were plated in DMEM at 10% confluence. After 24 hours, cells were switched to dropout DMEM supplemented with 5% dialyzed FBS (Thermo). This medium was further supplemented with 0% or 5% cell culture-grade bovine serum albumin (BSA; Sigma), which was not fatty acid free. For assaying growth in amino acid-free DMEM, cells passaged in leucine-free DMEM supplemented with 5% BSA were plated at 20% confluence. After 24 hours, medium was changed to amino acid-free DMEM with 5% BSA. Medium was replaced as needed.

Imaging and cell counting

For imaging, cells were fixed in 10% TCA for 15 minutes, and images were obtained using a Nikon Eclipse TE2000-U microscope operated by Q-Capture Pro software (QImaging). KRPC

cells growing in leucine-free medium supplemented with BSA were seeded at 10% confluence and switched to fresh leucine-free medium after 24 hours. Cell proliferation was assessed by cell number determination using a Countess Automated Cell Counter (Invitrogen) or by determining total packed cell volume (PCV) using PCV tubes (Techno Plastic Products).

Stable isotope tracing experiments

Medium with fully ¹³C- and ¹⁵N-labeled glucose and amino acids, otherwise equivalent to DMEM, was reconstituted from individual components (¹³C- and ¹⁵N-DMEM). This medium contained unlabeled sodium bicarbonate and vitamins and was supplemented with 5% dialyzed FBS and 1% *v/v* penicillin-streptomycin (MP Biomedicals). After five doublings in this medium, cells were seeded at low cell density and switched to specified ¹³C- and ¹⁵N-labeled media. After 24 hours, metabolites were extracted and analyzed by liquid chromatography/mass spectrometry (LC/MS). Growth of KRPC cells in amino acid-free medium is dependent on pregrowth in leucine-free medium. Thus, cells were grown for five doublings in ¹³C- and ¹⁵N-DMEM then switched to leucine-free ¹³C- and ¹⁵N-DMEM with 5% BSA. After two to three doublings in this medium, cells were switched to (i) complete ¹³C- and ¹⁵N-DMEM with 5% BSA and (ii) amino acid-free ¹³C and ¹⁵N-DMEM with 5% BSA. Cells in complete medium were grown for 24 hours before metabolite extraction. Cells in amino acid-free medium were grown for 48 hours before metabolite extraction, with medium replaced after 24 hours.

Metabolite extraction from cultured cells

For analysis of intracellular amino acids, medium was aspirated and plates were rinsed three times with room temperature PBS. Metabolism was quenched and metabolites extracted in –80°C 80:20 methanol:water extraction solution. After 15 minutes at –80°C, plates were scraped and cell extracts were transferred to 15-mL conical tubes. Cell suspensions were vortexed, centrifuged at 3,000 × *g* for 5 minutes, supernatant was kept, and cellular debris was reextracted with –80°C 80:20 methanol:water extraction solution. The resulting suspension was centrifuged and the supernatant was combined with the supernatant from the first extraction. The resulting solution was dried under nitrogen flow and resuspended in high-performance liquid chromatography (HPLC)-grade water. Twenty microliters was added to 80-µL methanol in addition to 10-µL triethylamine and 2-µL benzyl chloroformate and incubated at room temperature for 30 minutes, to derivatize and thereby enhance measurement sensitivity of amino acids.

Tissue collection and metabolite extraction procedure

Patients undergoing surgical resection of pancreatic tumors consented to collection and analysis of their resected tissues. Following partial pancreas resection, approximately 100 mg segments of tumor and adjacent tissue were isolated and immediately frozen in liquid nitrogen, and the diagnosis of PDAC was confirmed histologically. The samples were shipped overnight on dry ice to Princeton University (Princeton, NJ) and stored in liquid nitrogen until analysis.

Tumor and benign adjacent tissues of the same patient were prepared and analyzed in parallel. The samples were weighed and then pulverized by agitation with stainless steel balls at liquid nitrogen temperature (CryoMill, Retsch, 25 Hz for 3 minutes). The pulverized tissue was mixed by vortexing with 2 mL of –80°C

80:20 methanol:water, and split into two 1-mL replicate samples, which were set aside to extract for 5 minutes at -80°C . Each sample was centrifuged to isolate the soluble extract, and the insoluble material was extracted twice more with 1 mL 80:20 methanol:water for 5 minutes at 0°C and the supernatant again isolated by centrifugation. The supernatants from the three rounds of extraction were combined, dried under nitrogen gas, and reconstituted in LC/MS grade water (1 mL of water per 25 mg initial tissue weight).

LC/MS analysis

Cell culture and tissue samples were analyzed by three separate LC/MS systems: (i) Stand-alone orbitrap MS (Exactive; Thermo Scientific) operating in negative full scan mode at 100,000 resolution coupled to C18 ultra performance reversed-phase ion pair LC (17), (ii) triple quadrupole mass spectrometer (TSQ Quantum Discovery Max; Thermo Scientific) operating in negative multiple reaction monitoring mode coupled to C18 high-performance reversed-phase ion pair LC, and (iii) triple quadrupole mass spectrometer (TSQ Quantum Ultra; Thermo Scientific) operating in positive multiple reaction monitoring mode coupled to Hydrophilic interaction liquid chromatography (HILIC) chromatography (18). Metabolites were identified by accurate mass (<5 ppm deviation, Exactive) or characteristic fragmentation product (triple quads), in combination with retention time match to validated standards, using in-house software (19). Linearity of response was verified by running 2-fold dilutions of most samples and observing 2-fold decreases in peak intensities. For a subset of tissue samples, amino acid concentrations were determined using ^{13}C -labeled amino acid standards. For quantification of amino acid pool sizes in cultured cells, metabolite intensities were normalized by PCV. Cell culture leucine measurements were obtained using a modified HILIC method (20).

Ex vivo macropinocytosis assay

Fresh PDAC tumor tissue obtained from surgical resections was cut into slices with an approximate 3-mm cuboidal shape. Tissue was immersed into serum-free DMEM containing 1 to 2 mg/mL of TMR-dextran and incubated at 37°C for 20 to 30 minutes. Tissue was rinsed twice in PBS and immediately frozen in optimal cutting temperature (OCT) compound. Tissue processing and image analysis was performed as previously described (21).

Data normalization and processing of tissue metabolomic data

Ion counts were normalized to correct for differences in total metabolite abundances across samples, and for any sample-to-sample drift in the overall instrument response factor. A normalization factor (γ_i) was calculated for each LC/MS run i . To calculate γ_i , every known metabolite peak P_{mi} in LC/MS run i was quantified, and compared with the median value of peak m across all samples, μ_m . The scaling factor was calculated according to Eq. 1:

$$\gamma_i = \text{median}\left(\frac{P_{mi}}{\mu_m}\right) \quad (1)$$

and ion counts were corrected accordingly: $P_{mi}^* = \frac{P_{mi}}{\gamma_i}$.

The normalized ion count matrix was \log_2 -transformed and averaged over replicates. When a metabolite was measured on multiple instruments, the results were averaged.

Significance testing of tumor/benign adjacent tissue metabolite differences

To determine whether a subset of metabolites are systematically higher or lower in cancerous than in benign adjacent pancreatic tissue, P values were computed using a paired t test with the null distribution generated by bootstrapping (22). This method was chosen as a more conservative alternative to determining the test significance against a t -distribution, because the parametric t -distribution approach makes the assumption that the log-metabolite abundances are each normally distributed. This assumption is not valid for many metabolites.

For a given metabolite m , measured in n patients, tumor metabolite abundance (C_{mi}) was compared within the same patient to the benign tissue metabolite abundance (B_{mi}). These abundances, $[B_{mi}, C_{mi}]$, were jointly standardized so that they collectively have a mean of 0 and a standard deviation of 1. The systematic difference between pairs can be captured by a paired t test statistic (Eq. 2).

$$t_m = \frac{\sum_{i=1}^n \frac{(B_{mi} - C_{mi})}{n}}{\sqrt{\frac{\sum_{i=1}^n \frac{(B_{mi} - C_{mi})^2}{n-1}}{n}}} \quad (2)$$

To generate samples for an empirical null distribution, we need to generate data where the systematic variation between the benign and cancer samples has been removed and then use the remaining variation to determine how often we would have seen such a large systematic difference (t_m) by chance. To generate these null data, the paired difference was removed from the benign abundances (Eq. 3a), the modified abundances were recentered (Eq. 3b) and then these residuals were corrected for the 1 degree of freedom eliminated by removing the paired difference (Eq. 3c), as per Efron and Tibshirani (22).

$$B_{mi}^* = B_{mi} - \frac{\sum_{i=1}^n (B_{mi} - C_{mi})}{n} \quad (3a)$$

$$M_m = \text{mean}[B_{mi}^*, C_{mi}] \quad (3b)$$

$$B_{mi}^r = (B_{mi}^* - M_m) \sqrt{\frac{n}{n-1}} \quad (3c)$$

$$C_{mi}^r = (C_{mi} - M_m) \sqrt{\frac{n}{n-1}}$$

For each bootstrap sample (500,000 were used), n patients were randomly sampled (with replacement) and the pairs of null data from these patients (drawn from B_{mi}^r and C_{mi}^r) formed B_{mi}^b and C_{mi}^b . Because there are no systematic differences between the means of B_{mi}^r and C_{mi}^r , t statistics of these null pairs (Eq. 4) can be used to approximate the distribution of t statistics expected under the null hypothesis.

$$t_{mr}^b = \frac{\sum_{i=1}^n \frac{(B_{mi}^b - C_{mi}^b)}{n}}{\sqrt{\frac{\sum_{i=1}^n \frac{(B_{mi}^b - C_{mi}^b)^2}{n-1}}{n}}} \quad (4)$$

A P value for metabolite m can be calculated by determining how often a t statistic more extreme than the observed statistic (t_m) would be expected under the null hypothesis (Eq. 5).

$$p_m = 1 - \frac{\sum_r^R |t_m| > |t_{mr}^b|}{R} \quad (5)$$

False discovery rate calculation

Correction for multiple hypothesis testing followed the procedure of Storey and Tibshirani (23). Briefly, if there are no metabolites that systematically differ between benign tissue and tumors (i.e., all of the metabolites are true negatives), then the expected distribution of P values across all metabolites is uniform on $[0,1]$. To the extent that some of the metabolites do systematically differ, the associated P value histogram will be a mixture of true positive P values (skewed toward zero) and uniform true negatives. This histogram allows us to estimate the fraction of true negatives in the dataset: π_0 . We can then find a P value cutoff, q , corresponding to the desired false discovery rate (FDR), by taking the ratio of the expected number of false positives ($\pi_0 m q$) to the number of P values less than q . Metabolites with P values less than this q -value were treated as discoveries.

Results

Metabolomic analysis of human PDAC tumors

Paired PDAC tumor and benign adjacent tissue specimens were acquired by surgical resection from 49 patients (Fig. 1A). To minimize metabolic changes during the tissue acquisition process, the preferred technique is freeze-clamping *in situ* with liquid nitrogen-cooled Wollenberger tongs (24, 25). Such *in situ* freeze-clamping might compromise clinical outcomes, for example, by precluding proper identification of tumor margins. Accordingly, we instead relied on excised samples, with the surgical approach chosen to maintain perfusion until just before excision. Thereafter, tumor and benign adjacent tissue samples were rapidly quenched in liquid nitrogen and stored at $\leq -70^\circ\text{C}$. Metabolome analysis was conducted at the whole sample level, without distinguishing between epithelial and stromal tumor components. Paired samples were extracted in parallel and analyzed by three complementary LC/MS methods that enabled quantitation of 127 water-soluble metabolites across a majority of the samples (17).

Of the 127 metabolites examined, 57 displayed significantly different levels in pair-wise analysis of tumor and benign adjacent tissue (Fig. 1B). The most strongly depleted metabolites in tumors were glutamine, cytidine (whose amino group is derived from glutamine), guanidoacetic acid (a precursor to creatine phosphate, which was also down), glucose, and several phosphorylated compounds derived from glucose (glucose-6-phosphate, sedoheptulose-7-phosphate, and glycerol-3-phosphate). The most strongly increased metabolites in tumors were the DNA base thymine and several hydrophobic essential amino acids (valine, isoleucine/leucine, and tryptophan). The tryptophan degradation product kynurenine, which has immunosuppressant bioactivity (26), was also strongly elevated in the tumors.

Within central carbon metabolism glucose, glucose-6-phosphate, and fructose-6-phosphate were all decreased in the tumors, as were most TCA cycle compounds. In contrast, the 3-carbon glycolytic intermediates dihydroxyacetone phosphate and 3-phosphoglycerate were slightly increased, as was lactate. Collectively, these observations are consistent with increased propensity for aerobic glycolysis but decreased glucose availability in the tumors.

As a class, the 20 proteogenic amino acids showed particularly strong changes between the tumor and benign adjacent tissue with some amino acids strongly increased in the tumors, and others strongly decreased. There was the propensity for "nonessential" amino acids to be depleted in the tumors, whereas

"essential" amino acids accumulated to higher levels (compare green and red bars in Fig. 1B). This trend, however, was not absolute. Most importantly, while glutamine was the most depleted amino acid (with an average depletion of 2.5-fold verified using ^{13}C -labeled internal standards; Supplementary Table S1), glutamate (which differs from glutamine by a single amine moiety) was slightly increased. This led us to consider the hypothesis that the observed patterns of amino acid depletion and accumulation might not reflect amino acid essentiality, but rather rates of individual amino acid consumption by anabolic pathways. Specifically, the two most depleted amino acids, glutamine and serine, play key anabolic roles as amine- and one-carbon donors, respectively. In addition, serine is a key precursor of lipid head groups, and both CDP-choline and CDP-ethanolamine levels were increased in tumors. In contrast, levels of amino acids used primarily for protein synthesis were increased in PDAC.

This pattern of amino acid levels in the tumors is consistent with amino acids being acquired by protein catabolism to fuel anabolic metabolism (Fig. 1C; ref. 14). Although uptake or synthesis of monomeric amino acids would be expected to produce each amino acid in the appropriate amount, protein catabolism instead produces all amino acids in proportion to their abundance in protein. Those amino acids that are consumed by multiple anabolic processes (such as glutamine) accordingly become depleted relative to those used solely or primarily for protein synthesis.

Macropinocytosis in PDAC tumors

Macropinocytosis mediates the endocytic uptake of extracellular protein in RAS-driven cancer cells and murine tumors (14). Therefore, to examine whether this protein internalization mechanism is active in human PDAC tumor tissue, freshly acquired human tumor specimens were incubated with high molecular weight tetramethylrhodamine-conjugated dextran (TMR-dextran), an established marker of macropinosomes, and intracellular uptake of TMR-dextran was assessed by fluorescent microscopy of tissue sections. TMR-positive macropinosomes were detected in CK19-positive tumor cells (Fig. 2). Quantitatively lower, but nevertheless substantial, TMR-dextran staining was also detected in CK19-negative tumor tissue, which may include both stromal cells and PDAC cells that have undergone epithelial-mesenchymal transition (thereby losing CK19; Supplementary Fig. S1). In contrast, few macropinosomes were detected in normal adjacent tissue (Supplementary Fig. S2). Although some intratumoral variability was observed, stimulated macropinocytosis was evident in each of the five analyzed PDAC tumor samples. These data indicate that macropinocytosis is an attribute of human pancreatic tumors and that pancreatic cancer cells have the capacity to take up fluids and their constituents from the tumor extracellular environment.

Support of cultured tumor cell growth by albumin in the absence of free amino acids

Prior work has shown that macropinocytosis enables KRAS-activated cells to proliferate in low glutamine media supplemented with albumin (14). However, the extent to which protein scavenging can provide other amino acids in quantities sufficient to support cellular proliferation remains unknown. To address this question, we incubated KRAS-driven pancreatic cells in medium lacking one or more essential amino acids and supplemented with physiologic levels of albumin. Murine-derived pancreatic




Figure 1. Metabolomic analysis of human PDAC compared with benign adjacent pancreatic tissue. A, schematic of experimental procedure: PDAC and benign adjacent tissue from $n = 49$ patients were collected during pancreatic resection, frozen in liquid nitrogen, grounded, extracted, and subjected to metabolite analysis by LC/MS. B, metabolites with significantly different levels between tumor and paired benign adjacent tissues (FDR < 0.05). Y-axis is the ratio of metabolite concentrations in the tumor to benign adjacent tissue. Vertical lines represent range, boxes interquartile range, and horizontal lines median across the 49 patients. C, schematic illustration of possible mechanism underlying essential amino acid accumulation: protein catabolism yields amino acids in the ratio found in protein; those used extensively for purposes other than making new protein are depleted, while the others buildup.

cancer cells with oncogenic KRAS^{G12D} and silenced P53 (KRPC cells; ref. 16), growing in complete medium were switched to leucine-deficient medium either (i) not supplemented with BSA or (ii) supplemented with the typical circulating concentration of

BSA (50 g/L or 5%). As expected, KRPC cells did not survive in leucine-free medium without added BSA. In contrast, when switched to leucine-free medium supplemented with BSA, leucine removal initially resulted in extensive cell death, but surviving




Figure 2.

Human pancreatic tumor cells display macropinocytosis. A, hematoxylin and eosin (H&E) staining of tissue from a representative human pancreatic tumor. Scale bar, 100 μm . B and C, an *ex vivo* macropinocytosis uptake assay using TMR-dextran as a marker of macropinosomes (red) indicates that CK19-positive pancreatic tumor cells (green) display high levels of macropinocytosis. DAPI staining (blue) identifies nuclei. Cell boundaries (red outline) in B were delineated on the basis of CK19 staining. The images shown in C represent a higher magnification of the boxed areas in B. For B and C, the scale bars are 20 μm and 5 μm , respectively. Images shown are Z-stack projections and are representative of five independent tumors.

cells proliferated indefinitely (months) with a doubling time of approximately 24 hours (Fig. 3A and B and Supplementary Fig. S3). After 24 hours in this medium, the intracellular leucine concentration in these cells was approximately 12.5 pmol/ μL cell volume, roughly 100-fold lower than in the same cells grown in complete medium, but twice as high as in cells cultured in the absence of both leucine and BSA (Fig. 3C). KRPC cells were also able to proliferate indefinitely in the absence of lysine or phenylalanine (Supplementary Fig. S4).

One trivial explanation for the growth of KRPC cells in medium without leucine is trace leucine contamination from serum or other additives in quantities sufficient to support cell growth. To rule out this possibility, we added 12 $\mu\text{mol/L}$ leucine to leucine-free medium that was not supplemented with BSA. LC/MS measurements revealed that, while this leucine-spiked medium contained more free leucine than the BSA-supplemented leucine-free medium (Supplementary Fig. S5), it did not support cell growth. Therefore, the continuous proliferation of KRPC cells in leucine-free medium supplemented with albumin is not due to contaminating leucine.

Given that KRPC cells can use intact protein as their sole source of leucine, lysine, or phenylalanine, we wondered whether these cells could proliferate in BSA-supplemented medium without any free amino acids. We switched KRPC cells growing in leucine-free medium to amino acid-free medium either (i) not supplemented with BSA or (ii) supplemented with 5% BSA. Although the amino acid-free medium without BSA supplementation did not support cell survival, cells switched to the BSA-supplemented amino acid-free medium grew to confluence, doubling once over a period of 5 days (Fig. 3D and E). Thus, KRAS-driven cancer cells *in vitro* can grow faster than PDAC tumor cells *in vivo* solely through scavenging and subsequent catabolism of extracellular protein.

Isotope tracing of serum protein catabolism

The capability of RAS-mutant cells to proliferate in the absence of essential amino acids suggests that serum protein catabolism

might contribute substantially to their amino acid pools. To quantitatively measure this contribution, we developed an isotope tracer-based method enabling separate quantitation of (i) amino acids initially taken up as monomers and (ii) amino acids acquired via catabolism of serum protein. We prepared growth medium in which natural glucose and all amino acids were replaced by uniformly ^{13}C - and ^{15}N -labeled glucose and amino acids at standard DMEM concentrations (^{13}C - and ^{15}N -DMEM). KRPC cells were grown in this medium for five doublings, such that cellular protein in the resulting population was predominantly labeled. Then, cells were transferred to ^{13}C - and ^{15}N -medium equivalent to DMEM except that free amino acids were present at 10% of their DMEM concentrations (^{13}C - and ^{15}N -DMEM, 10% AA). These amino acid concentrations more closely resemble physiologic conditions [e.g., average human PDAC glutamine concentration is 700 $\mu\text{mol/L}$ (Supplementary Table S1), and 10% of DMEM glutamine concentration is 400 $\mu\text{mol/L}$]. Use of this medium is important for detecting unlabeled amino acids coming from protein catabolism, whose concentrations are otherwise overwhelmed by the high amino acid concentrations in full DMEM. The cells were cultured for 24 hours in this medium, and metabolites were extracted and analyzed by mass spectrometry (Fig. 4A).

In cells grown without added albumin, less than 12% of intracellular and less than 5% of extracellular essential amino acids were unlabeled. These observed unlabeled amino acids are presumably derived primarily from catabolism of the available serum protein (the cells were cultured in 5% FBS). The addition of albumin dramatically increased the observed levels of unlabeled (i.e., serum protein-derived) intracellular amino acids (Fig. 4B). Moreover, substantial concentrations of unlabeled amino acids were also observed in the medium, suggesting rapid exchange of intracellular and extracellular amino acid pools (Fig. 4C). Contribution from albumin to intracellular amino acid pools was also observed in MIA PaCa-2 and E3 human pancreatic cancer cells (Supplementary Fig. S6). Thus, we were able to directly track




Figure 3. RAS-mutant pancreatic cells are capable of growth in medium lacking essential amino acids when supplemented with physiologic levels of serum protein. A and B, images of KRPC cells cultured in leucine-free medium. The cells survive and proliferate in the presence of 50 g/L BSA. B, cell counts from A. C, intracellular leucine concentrations in KRPC cells grown in leucine-rich and leucine-free media, as measured by LC/MS. D and E, KRPC cells cultured in amino acid-free medium grow using serum protein as their sole source of amino acids. For B–D, data are means \pm SE, $n \geq 3$.

amino acids derived from protein catabolism in cultured PDAC cells.

We next sought to validate the hypothesis that catabolism of serum protein occurs in the lysosome by treating KRPC cells with bafilomycin A1, which impairs lysosomal function by inhibiting the vacuolar-type H^+ -ATPase (27). Treatment of KRPC cells with bafilomycin A1 resulted in a dose-dependent reduction of amino acids derived from serum protein catabolism (Fig. 4D and E). Treatment with EIPA, a canonical inhibitor of macropinocytosis (14), also results in a reduction in serum protein–derived amino acids in KRPC cells (Supplementary Fig. S7). Taken together, these data demonstrate that, even in the absence of amino acid deprivation, lysosomal degradation of extracellular protein contributes substantially to PDAC amino acid pools.

Amino acid patterns in cells fed by serum protein macropinocytosis

We next used our isotope tracing strategy to confirm that cells grown in amino acid–free media supplemented with 5% BSA acquire most of their amino acids from the unlabeled extracellular protein. With the exception of alanine, serine, and


glycine, which were synthesized from glucose (which, in contrast to the pancreatic cancer microenvironment, was abundant in the culture media), all amino acids were largely unlabeled, that is, derived from extracellular protein (Fig. 5A). In addition, amino acid nitrogen in these cells was predominantly extracellular protein derived (Supplementary Fig. S8).

We next asked how amino acid concentrations differed between cells grown in amino acid–free medium supplemented with physiologic albumin and cells grown in standard DMEM. Growth in the albumin-supplemented, amino acid–free medium resulted in strong depletion of intracellular glutamine after 24 hours in culture (Fig. 5B). However, paradoxically we observed accumulation of essential amino acids to levels comparable with, and in some cases greater than, those seen in cells grown in rich medium (Fig. 5C). Moreover, significant concentrations of free amino acids were excreted into the medium (Fig. 5D and E). As the tumor metabolomic analysis does not allow for discrimination between cancer cell intracellular and extracellular amino acid pools, we are unable to determine whether amino acid excretion occurs *in vivo*. In addition, perhaps due either to differences in nutrient availability between the actual tumor and this cell culture model (e.g., of glucose, free amino acids, albumin, and other proteins) or to the substantial fraction of stroma in the tumor, there was not a direct correspondence between amino acid concentration changes in the PDAC tumors and cells grown in albumin-supplemented amino acid–free medium. Nevertheless, these data confirm that growth fed by scavenging of extracellular protein can lead to glutamine depletion and essential amino acid accumulation.

Discussion

The definition of cancer is the uncontrolled division and growth of cells. To facilitate this, cancer cells need nutrients that can be used to generate the necessary energy and cellular building blocks. It is commonly assumed that cancers primarily rely on glucose and glutamine as their nutrient sources. The dependence on glucose is certainly true for many cancers and is perhaps best illustrated by the clinical value of FDG-PET, which uses a glucose analogue to image and stage tumors (28). However, there are exceptions, with a notable example being PDAC: less than 25% of tumors are markedly FDG-PET positive, and up to 35% do not take up FDG above background (29). This may be caused by restricted blood perfusion due to the high interstitial pressure and desmoplasia that are characteristic for PDAC (30). Despite a limited availability of free glucose and glutamine, PDAC is notoriously aggressive, suggesting that other nutrients may play an important role in fueling PDAC growth.

What could these alternative nutrients be? We recently reported the ability of KRAS-transformed cells to uptake extracellular protein through macropinocytosis (14), and to use serum lipids to support growth (31). PDAC cells reuse the amino acids and fatty acids from these extracellular proteins and lipids to support growth, much as they also rely on recycling of intracellular materials via autophagy to survive metabolic stress (32, 33). Leaky tumor vasculature and lymphatics can result in accumulation of albumin and other serum proteins in the tumor interstitium. Scavenging of proteins and lipids diminishes demand for



de novo biosynthesis and thus the need for glucose and free glutamine-derived carbon, reducing equivalents (NADH and NADPH), and ATP.

As some key metabolic pathways are oxygen-dependent (TCA cycle and fatty acid desaturation), bypassing them facilitates growth in hypoxia. Oncogenic RAS, even in nutrient and oxygen replete conditions, reduces oxygen consumption and increases macropinocytosis and lipid scavenging (5, 6, 31). It thus appears that RAS prepares cells to survive and grow in metabolically harsh conditions, including hypoxia.

Here, we provide an in-depth analysis of the metabolic state of primary human PDAC tumors. PDAC tumor tissues are heterogeneous, characterized not only by the presence of tumor cells, but also cancer-associated fibroblasts, immune cells, and extracellular matrix. Our analyses do not allow us to differentiate between the metabolic contributions from each of these compartments. Rather, they represent the metabolic state of the tumor tissue as a whole. Using this approach, we found that relative to the benign adjacent tissues, PDAC tumors were consistently low in both glucose and glutamine. We further found a pattern of amino acid levels consonant with what would happen if the tumors were largely reliant on protein scavenging (Fig. 1C): a differential utilization of amino acids for purposes other than protein synthesis (nucleotide and lipid synthesis etc.) leaves amino acids primarily used for protein synthesis to build up, whereas amino acids used for other purposes as well (glutamine, serine, and alanine) deplete.

By culturing cells in the absence of one or all free essential amino acids, we were able to demonstrate the capacity of

extracellular protein scavenging to provide amino acids to support growth. Intriguingly, cells were able to grow rapidly and indefinitely by this mode of consumption in the absence of free leucine, lysine, or phenylalanine (which are all relatively abundant in albumin; Supplementary Fig. S9), and transiently in the absence of all free amino acids. Moreover, in the absence of all amino acids, BSA scavenging was sufficient to produce elevated intracellular levels of selected essential amino acids.

An increased scavenging ability allows cells to access vast resources of cellular building blocks and energy: assuming a total plasma protein concentration of 75 g/L, the amino acid content of plasma proteins exceeds free amino acids by approximately 200-fold. Thus, while poor perfusion may limit flow of all nutrients through the tumor, in such flow restriction, plasma protein may increase in relative importance as an amino acid source. In addition, plasma proteins are also a major potential energy source, exceeding energy available in glucose by about 75-fold. Similarly, the ability to scavenge fatty acids from various serum lipids, rather than free fatty acids alone, increases available fatty acids by at least 4-fold (31).

Although blood flow is often low in PDACs due to the high interstitial pressure, tumor blood vessels are leaky. In combination with the fact that tumors are lymphatic deficient, this may result in plasma protein accumulation (15). In light of this, the recent clinical success of a protein-drug conjugate albumin-paclitaxel (nab-paclitaxel, Abraxane) in PDAC is particularly tantalizing (34), and warrants further investigation into metabolic scavenging and how it can be exploited therapeutically.




Figure 5. Cells relying on protein scavenging for amino acid assimilation accumulate strictly proteinogenic amino acids. KRPC cells were grown in amino acid-replete or amino acid-free medium and supplemented with physiologic levels of albumin. A, fractional contribution of serum protein-derived carbon to intracellular amino acid pools. B and C, relative intracellular amino acid abundances. D and E, net uptake or excretion of amino acids into the medium. Data are means \pm SE of $n \geq 3$.

Disclosure of Potential Conflicts of Interest

M.G. Vander Heiden has ownership interest (including patents) in Agios Pharmaceuticals and is a consultant/advisory board member for the same. C.B. Thompson is a BOD at Merck, consultant at Agios Pharmaceuticals, and BOD at Charles River Laboratories; and has ownership interest (including patents) in Merck and Agios Pharmaceuticals. D. Bar-Sagi and C. Commisso have ownership interest (including patents) in New York University. J.D. Rabinowitz has received speakers' bureau honoraria from lectures given to biotechnology companies, has ownership interest (including patents) in Kadmon Corporation and Raze Therapeutics and is a consultant/advisory board member for the same, and is an inventor on patents filed by Princeton University. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: J.J. Kamphorst, M. Nofal, C. Commisso, J.A. Drebin, C.B. Thompson, J.D. Rabinowitz
Development of methodology: J.J. Kamphorst, M. Nofal, C. Commisso, Wenyun Lu, E. Grabocka, J.D. Rabinowitz
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.J. Kamphorst, M. Nofal, C. Commisso, Wenyun Lu, E. Grabocka, J.A. Drebin, D. Bar-Sagi
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.J. Kamphorst, M. Nofal, C. Commisso, S.R. Hackett, M.G. Vander Heiden, D. Bar-Sagi, J.D. Rabinowitz
Writing, review, and/or revision of the manuscript: J.J. Kamphorst, M. Nofal, C. Commisso, M.G. Vander Heiden, J.A. Drebin, D. Bar-Sagi, C.B. Thompson, J.D. Rabinowitz
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.J. Kamphorst
Study supervision: J.A. Drebin, J.D. Rabinowitz
Other (data collection): G. Miller

Acknowledgments

Troma-III, an antibody that recognizes CK19, was contributed by R. Kemler and made available by the Developmental Studies Hybridoma Bank under the auspices of the National Institute of Child Health and Human Development (NICHD). The authors also thank Thomas Shenk's laboratory for support with microscopy, Ian Lewis and Simon Cobbold for helpful discussions, and Scott Lowe for kindly providing the KRPC cells.

Grant Support

This work was supported by the NIH grants P50GM071508 (J.D. Rabinowitz), 1R01CA16359-01A1 (J.D. Rabinowitz), and 1R01CA055360 (D. Bar-Sagi), and by a Stand Up To Cancer Dream Team Translational Research Grant, Grant Number SU2C-AACR-DT0509. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. J.J. Kamphorst is a Hope Funds for Cancer Research Fellow (HFCR-11-03-01). The authors thank the NYU School of Medicine Biorepository Center, which is partially supported by the Cancer Center Support Grant, P30CA016087, at the Laura and Isaac Perlmutter Cancer Center. It is also supported, in part, by grant UL 1 TR000038 from the National Center for the Advancement of Translational Science (NCATS), NIH. The Histopathology Core of NYU School of Medicine is partially supported by the NIH (grant 5 P30CA016087-32).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 31, 2014; revised December 3, 2014; accepted December 3, 2014; published online February 2, 2015.

References

- Hidalgo M. Pancreatic cancer. *N Engl J Med* 2010;362:1605–17.
- Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012;491:399–405.
- Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sanankone E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. *Cell* 2012;149:656–70.
- Vander Heiden MG, Lunt SY, Dayton TL, Fiske BP, Israelsen WJ, Mattaini KR, et al. Metabolic pathway alterations that support cell proliferation. *Cold Spring Harb Symp Quant Biol* 2011;76:325–34.
- Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T, et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. *Mol Syst Biol* 2013;9:712.
- Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. *Mol Syst Biol* 2011;7:523–38.
- Son JJ, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. *Nature* 2013;496:101–5.
- Yun J, Rago C, Cheong J, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science* 2009;325:1555–9.
- Duffy JP, Eibl C, Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. *Mol Cancer* 2003;2:12.
- Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, et al. Pancreatic tumors show high levels of hypoxia. *Int J Radiat Oncol Biol Phys* 2000;48:919–22.
- Roberts E, Tanaka T. Free amino acids of the Yoshida ascites tumor. *Cancer Res* 1956;16:204–10.
- Roberts E, Frankel S. Free amino acids in normal and neoplastic tissues of mice as studied by paper chromatography. *Cancer Res* 1949;9:645–8.
- Bar-Sagi D, Feramisco JR. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by Ras proteins. *Science* 1986;233:1061–8.
- Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis as a mechanism of glutamine supply in Ras transformed cancer cells. *Nature* 2013;497:633–7.
- Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JCM, Hartung G, et al. Plasma protein (albumin) catabolism by the tumor itself—implications for tumor metabolism and the genesis of cachexia. *Crit Rev Oncol Hematol* 1997;26:77–100.
- Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. *Cancer Cell* 2014;25:697–710.
- Lu W, Clasquin MF, Melamud E, Amador-Noguez D, Caudy AA, Rabinowitz JD. Metabolomic analysis via reversed-phase ion-pairing liquid chromatography coupled to a stand alone orbitrap mass spectrometer. *Anal Chem* 2010;82:3212–21.
- Bajad SU, Lu W, Kimball EH, Yuan J, Peterson C, Rabinowitz JD. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. *J Chromatogr A* 2006;1125:76–88.
- Melamud E, Vastag L, Rabinowitz JD. Metabolomic analysis and visualization engine for LC-MS data. *Anal Chem* 2010;82:9818–26.
- Pesek JJ, Matyska MT, Fischer SM, Sana TR. Analysis of hydrophilic metabolites by high-performance liquid chromatography-mass spectrometry using a silica hydride-based stationary phase. *J Chromatogr A* 2008;1204:48–55.
- Commisso C, Flinn RJ, Bar-Sagi D. Determining the macropinocytic index of cells through a quantitative image-based assay. *Nat Protoc* 2014;9:182–92.
- Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. *Stat Sci* 1986;1:54–75.
- Storey JD, Tibshirani R. Statistical significance for genomewide studies. *Proc Natl Acad Sci U S A* 2003;100:9440–5.
- Wollenberger A, Ristau O, Schoffa G. [Eine einfache Technik der extrem schnellen Abkühlung grosserer Gewebestücke]. *Pflügers Archiv* 1960;270:399–412.
- Quistorff B, Pedersen E. A new device for the freeze-clamping of tissue samples. *Anal Biochem* 1976;73:236–9.
- González A, Varo N, Alegre E, Díaz A, Melero I. Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. *Adv Clin Chem* 2008;45:155–97.
- Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. *J Biol Chem* 1991;266:17707–12.
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 2009;324:1029–33.
- Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)—usefulness and limitations in "clinical reality." *Ann Nucl Med* 2003;17:261–79.
- Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. *J Cell Biochem* 2007;101:887–907.
- Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, White EP, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. *Proc Natl Acad Sci U S A* 2013;110:8882–7.
- Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic cancers require autophagy for tumor growth. *Genes Dev* 2011;25:717–29.
- Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. *Genes Dev* 2011;25:460–70.
- Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. *J Clin Oncol* 2011;29:4548–54.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein

Jurre J. Kamphorst, Michel Nofal, Cosimo Commisso, et al.

Cancer Res 2015;75:544-553.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/75/3/544>

Cited Articles This article cites by 34 articles, 12 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/75/3/544.full.html#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.